文献速递放射性药物与辐射防护

丙磺舒对人体全身6-溴-7-[11C]甲基嘌呤处置的影响:长轴视野PET/CT评估

Effect of probenecid on the whole-body disposition of 6-bromo-7-[11C]methylpurine in humans assessed with long axial field-of-view PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-02-08

七名健康志愿者在长轴视野PET/CT上接受两次动态全身[11C]BMP扫描,分别在不给予和预先口服单剂丙磺舒后。丙磺舒使尿清除率降低50±16%,并显著降低肾脏、肝脏、心肌、骨骼肌和视网膜的kE;脑内放射性清除缓慢,[11C]BMP似不适合测量人脑MRP1功能。

要点

  • 丙磺舒使[11C]BMP相关放射性的尿清除率降低50±16%。
  • 丙磺舒后肾脏kE降低43±20%,骨骼肌降低51±34%,视网膜降低57±29%(非血校正)。
  • 因脑内放射性清除缓慢,[11C]BMP似不适合测量人脑MRP1功能。

核心结论

  • 长轴视野PET/CT在全身、多组织水平评估药物处置和转运体介导的药物相互作用方面有较大潜力。
  • 由于[11C]BMP衍生的放射性从人脑清除缓慢,[11C]BMP似不适合测量人脑MRP1功能。
  • 但[11C]BMP可能用于评估各种外周组织中MRP1及可能其他MRP亚型的功能。

研究设计与样本

  • 七名健康志愿者(3名女性,4名男性)在长轴视野PET/CT系统上接受两次动态全身PET扫描。
  • 两次扫描分别在静脉注射[11C]BMP后不给予和预先口服单剂丙磺舒的条件下进行。
  • 为多个表达MRP的组织勾画感兴趣区:大脑皮质、小脑、脉络丛、视网膜、肺、心肌、骨骼肌、肾脏和肝脏。
  • 组织时间-放射性曲线经血管放射性贡献校正后,计算消除速率常数kE(h-1)作为组织MRP功能的参数。
  • 试验注册号EudraCT 2021-006348-29,注册日期2021年12月15日。

主要发现

  • 放射性主要排入尿膀胱,给予丙磺舒后尿清除率显著降低(-50±16%)。
  • 给予丙磺舒后,肾脏kE显著降低(-43±20%)。
  • 给予丙磺舒后,肝脏kE显著降低(-18±15%)。
  • 给予丙磺舒后,心肌kE显著降低(-16±12%)。
  • 给予丙磺舒后,骨骼肌kE显著降低(-51±34%),视网膜kE显著降低(-57±29%,非血校正)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Multidrug resistance-associated proteins (MRPs) have a widespread tissue distribution. They play an important role in drug disposition and drug-drug interactions (DDIs) and have been associated with various diseases. PET with 6-bromo-7-[11C]methylpurine ([11C]BMP) has been used to assess MRP1 function in the brain and lungs of mice. [11C]BMP crosses cellular membranes by passive diffusion followed by intracellular conjugation with glutathione and MRP1-mediated efflux of the radiolabelled glutathione-conjugate. In this study, we assessed the effect of the prototypical organic anion transporter inhibitor probenecid on the whole-body disposition of [11C]BMP to examine its suitability for measuring the function of MRP1 and possibly other MRP subtypes across multiple tissues. METHODS: Seven healthy volunteers (3 women, 4 men) underwent two dynamic whole-body PET scans on a long axial field-of-view (LAFOV) PET/CT system after intravenous injection of [11C]BMP, without and with pre-treatment with a single oral dose of probenecid. Volumes of interest were outlined for several MRP-expressing tissues (cerebral cortex, cerebellum, choroid plexus, retina, lungs, myocardium, skeletal muscle, kidneys, and liver). Tissue time-activity curves were corrected for the contribution of vascular radioactivity and the elimination rate constant (kE, h- 1) was calculated as a parameter for tissue MRP function. RESULTS: Radioactivity was primarily excreted into the urinary bladder and urinary clearance was significantly decreased after probenecid administration (- 50 ± 16%). Following probenecid administration, kE was significantly decreased in the kidneys (- 43 ± 20%), liver (- 18 ± 15%), myocardium (- 16 ± 12%), skeletal muscle (- 51 ± 34%), and retina (- 57 ± 29%, non-blood-corrected). CONCLUSION: Our study highlights the great potential of LAFOV PET/CT to assess drug disposition and transporter-mediated DDIs in humans at a whole-body, multi-tissue level. Due to the slow elimination of [11C]BMP-derived radioactivity from the human brain, [11C]BMP appears unsuitable to measure cerebral MRP1 function in humans, but it may be used to assess the function of MRP1 and possibly other MRP subtypes in various peripheral tissues. TRIAL REGISTRATION: EudraCT 2021-006348-29. Registered 15 December 2021.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Jackwerth M, Mairinger S, Rausch I, et al. Effect of probenecid on the whole-body disposition of 6-bromo-7-[11C]methylpurine in humans assessed with long axial field-of-view PET/CT. Eur J Nucl Med Mol Imaging. 2025. PMID: 39920267. doi:10.1007/s00259-025-07121-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。